Allarity closes $20M financing for stenoparib advancement

Core Viewpoint - Allarity Therapeutics has successfully closed a $20 million non-convertible debt financing with Streeterville Capital, which is expected to extend its cash runway into the summer of 2028 [1]. Financing Details - The financing is structured as a note purchase agreement, involving two non-convertible promissory notes: one with an original principal amount of $10,930,000 and another secured promissory note of $10,000,000, together providing approximately $20 million in net proceeds to the Company [1]. Use of Proceeds - The Company plans to utilize the proceeds primarily to support key initiatives aimed at accelerating the development of stenoparib towards pivotal development, FDA approval, and commercialization [1].